Tag: Alkido Pharma Inc.

AIkido Pharma Inc. Regains Compliance with NASDAQ Listing Requirements

NEW YORK, June 28, 2022 /PRNewswire/ — AIkido Pharma Inc. (Nasdaq: AIKI) (“AIkido” or the “Company”) today announced that on June 23, 2022, the Company received a letter from the Listing Qualifications Department of The NASDAQ Stock Market indicating that it has regained compliance with the $1.00 minimum bid price requirement for continued listing on The NASDAQ Capital Market under Listing Rule 5550(a)(2). The Company regained compliance with the NASDAQ’s requirements when the closing bid price for the Company’s common stock was at or above $1.00 for 10 consecutive business days and the matter is now closed.

About AIkido Pharma Inc.

AIkido Pharma Inc. was initially formed in 1967 and is a biotechnology Company with a diverse portfolio of small-molecule anticancer and antiviral therapeutics. The Company’s platform consists of patented technology from leading universities and researchers, and we are currently in the process of developing an innovative therapeutic drug platform through strong partnerships with world renowned educational institutions, including The University of Texas at Austin and University of Maryland at Baltimore. Our diverse pipeline of therapeutics includes therapies for pancreatic cancer, prostate cancer. We are constantly seeking to grow our pipeline to treat unmet medical needs in oncology. The Company is also developing a broad-spectrum antiviral platform that may potentially inhibit replication of multiple viruses including Influenza virus, SARS-CoV (coronavirus), MERS-CoV, Ebolavirus and Marburg virus.

Forward-Looking Statements

Certain statements in this press release constitute “forward-looking statements” within the meaning of the federal securities laws. Words such as “may,” “might,” “will,” “should,” “believe,” “expect,” “anticipate,” “estimate,” “continue,” “predict,” “forecast,” “project,” “plan,” “intend” or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including without limitation those set forth in the Company’s filings with the SEC, not limited to Risk Factors relating to its business contained therein. Thus, actual results could be materially different. The Company expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.

Contact:

Investor Relations: 

Hayden IR 
Brett Maas, Managing Partner 
Phone: (646) 536-7331 
Email: brett@haydenir.com 
www.haydenir.com

AIkido Pharma Inc. 
Phone: 212-745-1373 
Email: investorrelations@aikidopharma.com 
www.aikidopharma.com

SOURCE AIkido Pharma Inc.

AIkido Inc. Announces the Formation of a New Financial Services Subsidiary

Long-Range Strategy Seeks Diversification into Three Key Industries

NEW YORK, June 24, 2022 /PRNewswire/ — AIkido Pharma Inc. (Nasdaq: AIKI) (“AIkido” or the “Company”) announced the formation of a wholly owned subsidiary with the purpose of making strategic investments and acquisitions across the fintech and financial services industries. The new subsidiary is expected to be the centerpiece of a long-range plan to diversify AIkido’s business beyond biotechnology, in order to reduce volatility and mitigate risk while increasing revenue and enhancing shareholder value.

The new subsidiary will leverage the extensive capital markets expertise of AIkido’s board of directors to identify investment opportunities and acquisition targets in wealth management, investment banking, alternative investments, and asset management with the goal of transforming and optimizing operations with a synergistic and accretive business model. The Company is in the process of recruiting additional top-tier talent to implement the strategy.

Anthony Hayes, CEO of AIkido stated, “Our board is made up of some of the most accomplished Wall St. executives, so we are fully confident that the financial services sector is the right next step for AIkido and our overall plan is the right path forward for our company. Our vision is to merge world-class talent with best-in-class technology to acquire revenue generating assets to drive shareholder value,” Hayes added.

“Beyond acquisitions in the financial services industries, AIkido intends to create two additional subsidiaries in the industries of health and wellness and innovative technology. Our investment portfolio was set up along these same lines. For example, the legacy biotech assets and our investment in ASP Isotopes, Kerna Health, will be part of our health and wellness subsidiary. Whereas our investments in Epics Games, SpaceX, and Discord, are foundational to our innovation subsidiary. Our assets are part of a long-term strategy to own operational and revenue generating companies in the key high-growth sectors that we have identified for investment. The proceeds from the investments in each industry, some of which we expect to receive this year, will allow us to further fund and grow revenue generating businesses in those sectors. And just like financial services, the recruitment of top talent within each subsidiary is necessary for execution. We are committed as a Company to keep shareholders informed and will provide additional information when we are able. We thank shareholders for their patience and believe we have the proper plan to navigate through the notable downturn in the biotechnology sector and build a diversified company of revenue generating assets.”

About AIkido Pharma Inc.

AIkido Pharma Inc. was initially formed in 1967 and is a biotechnology Company with a diverse portfolio of small-molecule anticancer and antiviral therapeutics. The Company’s platform consists of patented technology from leading universities and researchers, and we are currently in the process of developing an innovative therapeutic drug platform through strong partnerships with world renowned educational institutions, including The University of Texas at Austin and University of Maryland at Baltimore. Our diverse pipeline of therapeutics includes therapies for pancreatic cancer, prostate cancer. We are constantly seeking to grow our pipeline to treat unmet medical needs in oncology. The Company is also developing a broad-spectrum antiviral platform that may potentially inhibit replication of multiple viruses including Influenza virus, SARS-CoV (coronavirus), MERS-CoV, Ebolavirus and Marburg virus.

Cautionary Note on Forward-Looking Statements

This press release and any statements of stockholders, directors, employees, representatives and partners of AIkido Pharma, Inc. (the “Company”) related thereto contain, or may contain, among other things, certain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements identified by words such as “projects,” “may,” “will,” “could,” “would,” “should,” “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “potential” or similar expressions. These statements are based upon the current beliefs and expectations of the Company’s management and are subject to significant risks and uncertainties, including those detailed in the Company’s filings with the Securities and Exchange Commission. Actual results (including, without limitation, the impact of the Reverse Stock Split described in this release) may differ significantly from those set forth or implied in the forward-looking statements. These forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company’s control). The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future presentations or otherwise, except as required by applicable law.

Contact:

Investor Relations:

Hayden IR
Brett Maas, Managing Partner
Phone: (646) 536-7331
Email: brett@haydenir.com
www.haydenir.com

AIkido Pharma Inc.
Phone: 212-745-1373
Email: investorrelations@aikidopharma.com
www.aikidopharma.com

SOURCE AIkido Pharma Inc.

AIkido Pharma Inc. Appoints New Director, Soo Yu

New Director Supports NASDAQ Rule on Diversity

NEW YORK, June 10, 2022 /PRNewswire/ — AIkido Pharma Inc. (Nasdaq: AIKI) (“AIkido” or the “Company”) today announced the appointment of Ms. Soo Yu, as a director of the Company. 

Anthony Hayes, CEO of AIkido stated, “At the time of the annual meeting, there was concern expressed by some shareholders about the Company’s compliance with the new NASDAQ rules on diversity.  The Company strongly believes in diversity and Ms. Yu is an exceptional candidate that also satisfies the new NASDAQ rule.  Further, Ms. Yu’s background broadens the experience and expertise of the Company, as we seek new areas of growth and opportunity for the Company.  We welcome Ms. Yu and look forward to her involvement.”

About Soo Yu

Soo Yu is the Managing Director of International Private Client Services for Revere Securities. With more than a decade of experience working in financial services, she focuses on international business development and the cultivation of overseas client banking relationships. A naturalized U.S. citizen originally from South Korea, Soo brings significant expertise in Asian markets and expansive global reach through her connectivity with international contacts.

Soo earned her B.A. in Fine Arts from the Fashion Institute of Technology and studied at the University of Nottingham and the Paris Fashion Institute. She holds Series 7 and Series 66 designations and her real estate license. Previously, she maintained her Series 79 and 24 licenses.

Soo actively supports several nonprofit organizations, including philanthropies committed to improving the lives of children and the elderly as well as sustainability.

Further information about Ms. Yu’s appointment to the Board are provided in the Company’s Form 8-K which was filed on June 10, 2022 with the Securities and Exchange Commission.

About AIkido Pharma Inc.

AIkido Pharma Inc. was initially formed in 1967 and is a biotechnology Company with a diverse portfolio of small-molecule anticancer and antiviral therapeutics. The Company’s platform consists of patented technology from leading universities and researchers, and we are currently in the process of developing an innovative therapeutic drug platform through strong partnerships with world renowned educational institutions, including The University of Texas at Austin and University of Maryland at Baltimore. Our diverse pipeline of therapeutics includes therapies for pancreatic cancer, prostate cancer. We are constantly seeking to grow our pipeline to treat unmet medical needs in oncology. The Company is also developing a broad-spectrum antiviral platform that may potentially inhibit replication of multiple viruses including Influenza virus, SARS-CoV (coronavirus), MERS-CoV, Ebolavirus and Marburg virus.

Forward-Looking Statements

Certain statements in this press release constitute “forward-looking statements” within the meaning of the federal securities laws. Words such as “may,” “might,” “will,” “should,” “believe,” “expect,” “anticipate,” “estimate,” “continue,” “predict,” “forecast,” “project,” “plan,” “intend” or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including without limitation those set forth in the Company’s filings with the SEC, not limited to Risk Factors relating to its business contained therein. Thus, actual results could be materially different. The Company expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.

Contact:

Investor Relations: 

Hayden IR 
Brett Maas, Managing Partner 
Phone: (646) 536-7331 
Email: brett@haydenir.com 
www.haydenir.com

AIkido Pharma Inc. 
Phone: 212-745-1373 
Email: investorrelations@aikidopharma.com 
www.aikidopharma.com

SOURCE AIkido Pharma Inc.

AIkido Announces Reverse Stock Split

NEW YORK, June 3, 2022 /PRNewswire/ — AIkido Pharma, Inc. (NASDAQ:AIKI), today announced that the Company’s Board of Directors has approved a reverse stock split of its shares of common stock at a ratio of 1 for 17 (the “Reverse Stock Split”). The Reverse Stock Split will become effective at 12:01 a.m. Eastern time on June 7, 2022 and the Company’s common stock will open for trading on The Nasdaq Capital Market on a post-split basis on June 7, 2022 under the Company’s existing trading symbol “AIKI”. At such time, the Company’s common stock will also commence trading under a new CUSIP number 0088753043.

We expect that the Reverse Stock Split, which was approved by stockholders at an annual stockholder meeting on May 20, 2022, will increase the market price per share of the Company’s common stock, bringing the Company into compliance with listing requirements for The Nasdaq Capital Market.

At the effective time of the Reverse Stock Split, every seventeen (17) shares of AIKI common stock issued and outstanding will be combined into one (1) share of common stock issued and outstanding, with no change to the par value of $0.0001 per share. This will reduce the Company’s outstanding common stock from approximately 89,294,446 million shares to approximately 5,252,555 million shares. Fractional shares resulting from the reverse stock split will be rounded down to the nearest whole share, and all currently issued shares of common stock held by a shareholder shall be aggregated for the purpose of determining whether the reverse stock split would result in the issuance of a fractional share. The shares and exercise prices, as applicable, underlying the Company’s outstanding equity awards and warrants will also be adjusted accordingly.

The Company’s transfer agent, Continental Stock Transfer & Trust Company (“Continental”) will provide stockholders of record holding certificates representing pre-split shares of the Company’s common stock as of the effective date, a letter of transmittal providing instructions for the exchange of shares. Registered stockholders holding pre-split shares of the Company’s common stock electronically in book-entry form are not required to take any action to receive post-split shares. Stockholders owning shares via a broker, bank, trust or other nominee will have their positions automatically adjusted to reflect the Reverse Stock Split, subject to such broker’s particular processes, and will not be required to take any action in connection with the Reverse Stock Split.

Additional information regarding the reverse stock split can be found in the Company’s definitive proxy statement (Form DEF 14A) filed with the U.S. Securities and Exchange Commission on April 12, 2022. Continental can be reached by phone at 917-262-2378

The Company does not anticipate raising any capital in the foreseeable future.

About AIkido Pharma Inc.

AIkido Pharma Inc. was initially formed in 1967 and is a biotechnology Company with a diverse portfolio of small-molecule anticancer and antiviral therapeutics. The Company’s platform consists of patented technology from leading universities and researchers, and we are currently in the process of developing an innovative therapeutic drug platform through strong partnerships with world renowned educational institutions, including The University of Texas at Austin and University of Maryland at Baltimore. Our diverse pipeline of therapeutics includes therapies for pancreatic cancer, prostate cancer. We are constantly seeking to grow our pipeline to treat unmet medical needs in oncology. The Company is also developing a broad-spectrum antiviral platform that may potentially inhibit replication of multiple viruses including Influenza virus, SARS-CoV (coronavirus), MERS-CoV, Ebolavirus and Marburg virus.

Cautionary Note on Forward-Looking Statements

This press release and any statements of stockholders, directors, employees, representatives and partners of AIkido Pharma, Inc. (the “Company”) related thereto contain, or may contain, among other things, certain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements identified by words such as “projects,” “may,” “will,” “could,” “would,” “should,” “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “potential” or similar expressions. These statements are based upon the current beliefs and expectations of the Company’s management and are subject to significant risks and uncertainties, including those detailed in the Company’s filings with the Securities and Exchange Commission. Actual results (including, without limitation, the impact of the Reverse Stock Split described in this release) may differ significantly from those set forth or implied in the forward-looking statements. These forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company’s control). The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future presentations or otherwise, except as required by applicable law.

Contact:

Investor Relations:

Hayden IR
Brett Maas, Managing Partner
Phone: (646) 536-7331
Email: brett@haydenir.com
www.haydenir.com

AIkido Pharma Inc.
Phone: 212-745-1373
Email: investorrelations@aikidopharma.com
www.aikidopharma.com

SOURCE AIkido Pharma Inc.

AIkido Pharma Announces Company Commitment to Board Diversity

NEW YORK , May 19, 2022 /PRNewswire/ — AIkido Pharma Inc. (Nasdaq: AIKI) (“AIkido” or the “Company”) today announced the Company’s commitment to complying with the NASDAQ listing requirements on board diversity by August 1, 2022 .

Anthony Hayes , CEO of AIkido stated, “Board diversity and inclusion is an important issue. We have been working towards meeting these requirements and today affirm that we will be adding a female board member on or before August 1, 2022 . We have several exceptional candidates and will be making an announcement on the new board member shortly. We further commit to continue to work towards more diversity and more inclusion in our board composition to more closely reflect the makeup of our diverse shareholder base.”

About AIkido Pharma Inc.

AIkido Pharma Inc. was initially formed in 1967 and is a biotechnology Company with a diverse portfolio of small-molecule anti-cancer therapeutics. The Company’s platform consists of patented technology from leading universities and researchers, and we are currently in the process of developing an innovative therapeutic drug platform through strong partnerships with world renowned educational institutions, including The University of Texas at Austin and University of Maryland at Baltimore . Our diverse pipeline of therapeutics includes therapies for pancreatic cancer and prostate cancer. We are constantly seeking to grow our pipeline to treat unmet medical needs in oncology. The Company is also developing a broad-spectrum antiviral platform that may potentially inhibit replication of multiple viruses including Influenza virus, SARS-CoV (coronavirus), MERS-CoV, Ebolavirus and Marburg virus.

Forward-Looking Statements

Certain statements in this press release constitute “forward-looking statements” within the meaning of the federal securities laws. Words such as “may,” “might,” “will,” “should,” “believe,” “expect,” “anticipate,” “estimate,” “continue,” “predict,” “forecast,” “project,” “plan,” “intend” or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including without limitation those set forth in the Company’s filings with the SEC, not limited to Risk Factors relating to its business contained therein. Thus, actual results could be materially different. The Company expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.

Contact:

Investor Relations:

Hayden IR
Brett Maas , Managing Partner
Phone: (646) 536-7331
Email: brett@haydenir.com
www.haydenir.com

AIkido Pharma Inc.
Phone: 212-745-1373
Email: investorrelations@AIkidopharma.com
www.AIkidopharma.com

View original content to download multimedia: https://www.prnewswire.com/news-releases/aikido-pharma-announces-company-commitment-to-board-diversity-301550922.html

SOURCE AIkido Pharma Inc.

AIkido Pharma Secures Interest in Databricks Inc.

Data and AI Company and a Pioneer of the Cutting-Edge Database Architecture

NEW YORK , May 12, 2022 /PRNewswire/ — AIkido Pharma Inc. (Nasdaq: AIKI) (“AIkido” or the “Company”) today announced that the Company, through a fund that owns the stock, has acquired an economic interest in privately held Databricks Inc.  ( https://databricks.com/company/about-us ).  The acquisition has been funded and closed, and the asset is on the Company’s balance sheet.

In an April 25, 2022 , article, Kiplinger listed Databricks as one of the “13 Hot Upcoming IPOs to Watch For in 2022,” reporting that “in August 2021 , … the firm raised $1.6 billion at a $38 billion valuation in a funding round led by Morgan Stanley fund Counterpoint Global.” ( https://www.kiplinger.com/investing/stocks/ipos/604149/hot-upcoming-ipos-to-watch-for-2022 ).  Similarly, in March 2022 , Forbes listed Databricks as one of the “10 Upcoming IPOs to Watch,” estimating an IPO in mid-2022 ( https://www.forbes.com/advisor/investing/upcoming-ipos/ ).  According to the article, “Databricks has become a leading purveyor of tools designed to simplify database management, implement AI and even just do great data visualization.  The company claims to have more than 5,000 clients in 19 countries and says it’s on track to generate $1 billion plus in 2022 revenue, up more than 75% year over year.” Included in Databricks’s list of investors are BlackRock, CapitalG, Fidelity, Microsoft and Andreessen Horowitz ( https://databricks.com/company/about-us ).

Yahoo! Finance has reported that “Microsoft Corp. is both a Databricks investor and a partner, integrating a version of the startup’s software into its cloud product, Microsoft Azure.”  ( https://www.yahoo.com/now/microsoft-backed-databricks-plans-ipo-000123816.html ).  According to the company’s website, “Databricks Lakehouse runs on every major public cloud, tightly integrated with the security, compute, storage, analytics and AI services natively offered by the cloud providers,” which, in addition to Microsoft Azure, include Amazon Web Services, Google Cloud and Alibaba Cloud . ( https://databricks.com/company/partners/cloud-partners ).

About AIkido Pharma Inc.

AIkido Pharma Inc. was initially formed in 1967 and is a biotechnology Company with a diverse portfolio of small-molecule anticancer and antiviral therapeutics. The Company’s platform consists of patented technology from leading universities and researchers, and we are currently in the process of developing an innovative therapeutic drug platform through strong partnerships with world renowned educational institutions, including The University of Texas at Austin and University of Maryland at Baltimore . Our diverse pipeline of therapeutics includes therapies for pancreatic cancer, prostate cancer. We are constantly seeking to grow our pipeline to treat unmet medical needs in oncology. The Company is also developing a broad-spectrum antiviral platform that may potentially inhibit replication of multiple viruses including Influenza virus, SARS-CoV (coronavirus), MERS-CoV, Ebolavirus and Marburg virus.

Forward-Looking Statements

Certain statements in this press release constitute “forward-looking statements” within the meaning of the federal securities laws. Words such as “may,” “might,” “will,” “should,” “believe,” “expect,” “anticipate,” “estimate,” “continue,” “predict,” “forecast,” “project,” “plan,” “intend” or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including without limitation those set forth in the Company’s filings with the SEC, not limited to Risk Factors relating to its business contained therein. Thus, actual results could be materially different. The Company expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.

Contact:

Investor Relations:

Hayden IR
Brett Maas , Managing Partner
Phone: (646) 536-7331
Email: brett@haydenir.com
www.haydenir.com

AIkido Pharma Inc.
Phone: 212-745-1373
Email: investorrelations@aikidopharma.com
www.aikidopharma.com

Glass Lewis Proxy Paper Report Recommends “FOR” AIkido Pharma Inc. Proposed Reverse Stock Split

Analysis Firm Agrees that Reverse Split Is in the Best Interest of the Company

NEW YORK, April 22, 2022 /PRNewswire/ — AIkido Pharma Inc. (Nasdaq: AIKI) (“AIkido” or the “Company”) today reported that, on April 20, 2022, the independent Proxy Paper analysis firm Glass Lewis issued a report (“GL Report”) providing an analysis of the proposals contained in the Company’s “Proxy Statement for 2022 Annual Meeting of Stockholders May 20, 2022,” which was filed with the Securities and Exchange Commission on April 12, 2022.  With respect to Proposal (4) in the Proxy Statement to effect a reverse split of the Company’s common stock, the GL Report recommends “FOR” the proposal. 

Anthony Hayes, CEO of AIkido, stated, “The Company’s Board of Directors strongly believes that the proposed reverse split is in the best interest of the Company and the stockholders. Importantly, the Reverse Split would not have any dilutive effect on our stockholders. The Board’s primary objective in proposing a potential reverse split is to raise the per share trading price of our common stock to allow the Company to regain compliance with the Nasdaq minimum bid requirement. The Board also believes that the proposed reverse split will enhance the acceptability and marketability of our common stock to the financial community and investing public. In its independent report, Glass Lewis recommends “FOR” the proposal and agrees with the Board that it is in the best interest of the Company. We encourage all shareholders to read the proxy information fully and carefully and then to vote your shares.”

For more information about Glass Lewis, see https://www.glasslewis.com/company-overview/.

About AIkido Pharma Inc.

AIkido Pharma Inc. was initially formed in 1967 and is a biotechnology Company with a diverse portfolio of small-molecule anticancer and antiviral therapeutics. The Company’s platform consists of patented technology from leading universities and researchers, and we are currently in the process of developing an innovative therapeutic drug platform through strong partnerships with world renowned educational institutions, including The University of Texas at Austin and University of Maryland at Baltimore. Our diverse pipeline of therapeutics includes therapies for pancreatic cancer, prostate cancer. We are constantly seeking to grow our pipeline to treat unmet medical needs in oncology. The Company is also developing a broad-spectrum antiviral platform that may potentially inhibit replication of multiple viruses including Influenza virus, SARS-CoV (coronavirus), MERS-CoV, Ebolavirus and Marburg virus.

Forward-Looking Statements

Certain statements in this press release constitute “forward-looking statements” within the meaning of the federal securities laws. Words such as “may,” “might,” “will,” “should,” “believe,” “expect,” “anticipate,” “estimate,” “continue,” “predict,” “forecast,” “project,” “plan,” “intend” or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including without limitation those set forth in the Company’s filings with the SEC, not limited to Risk Factors relating to its business contained therein. Thus, actual results could be materially different. The Company expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.

Contact:

Investor Relations: 

Hayden IR 
Brett Maas, Managing Partner 
Phone: (646) 536-7331 
Email: brett@haydenir.com 
www.haydenir.com

AIkido Pharma Inc. 
Phone: 212-745-1373 
Email: investorrelations@aikidopharma.com 
www.aikidopharma.com

SOURCE AIkido Pharma Inc.

AIkido Pharma Announces Strategic Investment in MasterClass

Masterclass Provides Members Access to Pre-Recorded Lectures by Top Experts

NEW YORK , April 5, 2022 /PRNewswire/ — AIkido Pharma Inc. (Nasdaq: AIKI) (“AIkido” or the “Company”) today announced that the Company has secured an early equity interest in privately-held Yanka Industries, Inc., doing business as MasterClass ( https://www.masterclass.com/ ). MasterClass is self-described as the “streaming platform where the world’s best come together so anyone, anywhere, can access and be inspired by their knowledge and stories. With an annual membership, members get unprecedented access to 150+ instructors and classes across a wide variety of fields, including Arts & Entertainment, Business, Design & Style, Sports & Gaming, Writing and more.” ( https://www.prnewswire.com/news-releases/masterclass-announces-professional-streamer-tyler-ninja-blevins-to-teach-how-to-become-a-streamer-in-30-days-301497337.html ).

In a December 21, 2021 article entitled “30 Startups We Think Could Go Public in 2022,” Crunchbase news stated, “it wouldn’t be a big surprise to see San Francisco -headquartered MasterClass dipping a toe in the public markets in coming months. The online education platform offers courses on a broad array of topics and features well-known figures including Malala Yousafzai , Spike Lee , Neil deGrasse Tyson and Ringo Starr . It reportedly had a valuation around $2.75 billion in May, more than tripling in value in the course of a year.” ( https://news.crunchbase.com/news/2022-startup-ipo-predictions-stripe-klarna-plaid-instacart-thrasio/ ).

Anthony Hayes , CEO of Aikido, stated, “The extraordinary content provided by MasterClass truly reflects its name.  We are amazed by the broad spectrum of topics and sheer number of prominent and renowned experts who have recorded the lectures provided by MasterClass’s service.  We are thrilled to be a part of this exceptional company, especially considering the potential it provides for value creation for our shareholders.  As some sectors of the market begin to slow down, we are constantly looking for opportunities that will augment shareholder value.”

In its news announcements, MasterClass has described itself as follows:

“ABOUT MASTERCLASS
“Founded in 2015, MasterClass makes it possible for anyone to learn from the best. With MasterClass, step into Anna Wintour’s office, Timbaland’s recording studio, and Neil Gaiman’s writing retreat. Improve your serve with Serena Williams , perfect your pitch with Shonda Rhimes, and leave the atmosphere with Chris Hadfield . Hundreds of video lessons from 85+ of today’s most brilliant minds are available anytime, anywhere on iOS, Android, desktop, Apple TV, Amazon Fire TV, Android TV and Roku devices with the All-Access Pass ( $180 /year). Subscribe to greatness with MasterClass.”

“MasterClass’s current roster of classes includes:

“Business: Howard Schultz (business leadership), Anna Wintour (creativity and leadership), Sara Blakely (self-made entrepreneurship), Bob Iger (strategy and leadership), Chris Voss (art of negotiation), Goodby and Silverstein (advertising and creativity), Robin Roberts (effective and authentic communication)

“Culinary Arts: Gordon Ramsay (cooking), Alice Waters (home cooking), Thomas Keller (cooking techniques), Wolfgang Puck (cooking), Dominique Ansel (French pastry), James Suckling (wine appreciation), Aaron Franklin (Texas BBQ), Massimo Bottura (Italian cooking), Gabriela Cámara (Mexican cooking), Lynnette Marrero and Ryan Chetiyawardana (mixology)

“Film and Television: Werner Herzog (filmmaking), Martin Scorsese (filmmaking), Ron Howard (directing), Spike Lee (filmmaking), Mira Nair (independent filmmaking), Jodie Foster (filmmaking), Ken Burns (documentary filmmaking), Helen Mirren (acting), Samuel L. Jackson (acting), Judd Apatow (comedy), Aaron Sorkin (screenwriting), Shonda Rhimes (writing for television), Natalie Portman (acting), David Lynch (creativity and filmmaking)

“Lifestyle: Bobbi Brown (makeup and beauty), RuPaul (self-expression and authenticity), Kelly Wearstler (interior design), Ron Finley (gardening)

“Music and Entertainment: Steve Martin (comedy), Christina Aguilera (singing), Usher (performance), Reba McEntire (country music), Herbie Hancock (jazz), Deadmau5 (music production), Armin van Buuren (dance music), Hans Zimmer (film scoring), Tom Morello (electric guitar), Carlos Santana (art and soul of guitar), Timbaland (producing and beatmaking), Penn & Teller (magic), Itzhak Perlman (violin), Danny Elfman (music for film), Sheila E. (drumming and percussion)

“Writing: James Patterson (writing), David Mamet (dramatic writing), Judy Blume (writing), Malcolm Gladwell (writing), R.L. Stine (writing for young audiences), Margaret Atwood (creative writing), Dan Brown (writing thrillers), Neil Gaiman (storytelling), Billy Collins (poetry), David Baldacci (writing thrillers), Joyce Carol Oates (short story writing), David Sedaris (storytelling and humor)

“Photography: Annie Leibovitz (photography), Jimmy Chin (adventure photography)

“Design and Fashion: Frank Gehry (architecture), Diane von Furstenberg (how to build a fashion brand), Marc Jacobs (fashion design)

“Sports and Games: Serena Williams (tennis), Stephen Curry (shooting, ball-handling, and scoring), Garry Kasparov (chess), Daniel Negreanu (poker), Phil Ivey (poker strategy), Simone Biles (gymnastics), Misty Copeland (ballet)

“Politics and Society: Jane Goodall (conservation), Bob Woodward (investigative journalism), Karl Rove and David Axelrod (political campaign strategy), Paul Krugman (economics and society), Doris Kearns Goodwin (U.S. presidential history and leadership)

“Science and Technology: Chris Hadfield (space exploration), Will Wright (game design), Neil deGrasse Tyson (scientific thinking and communication)

“For more information, please visit www.masterclass.com .”

(See, e.g., https://www.prnewswire.com/news-releases/masterclass-raises-100-million-in-series-e-funding-301062884.html )About AIkido Pharma Inc.

AIkido Pharma Inc. was initially formed in 1967 and is a biotechnology Company with a diverse portfolio of small-molecule anticancer and antiviral therapeutics. The Company’s platform consists of patented technology from leading universities and researchers, and we are currently in the process of developing an innovative therapeutic drug platform through strong partnerships with world renowned educational institutions, including The University of Texas at Austin and University of Maryland at Baltimore . Our diverse pipeline of therapeutics includes therapies for pancreatic cancer, prostate cancer. We are constantly seeking to grow our pipeline to treat unmet medical needs in oncology. The Company is also developing a broad-spectrum antiviral platform that may potentially inhibit replication of multiple viruses including Influenza virus, SARS-CoV (coronavirus), MERS-CoV, Ebolavirus and Marburg virus.Forward-Looking Statements

Certain statements in this press release constitute “forward-looking statements” within the meaning of the federal securities laws. Words such as “may,” “might,” “will,” “should,” “believe,” “expect,” “anticipate,” “estimate,” “continue,” “predict,” “forecast,” “project,” “plan,” “intend” or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including without limitation those set forth in the Company’s filings with the SEC, not limited to Risk Factors relating to its business contained therein. Thus, actual results could be materially different. The Company expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.

Contact:

Investor Relations:

Hayden IR
Brett Maas , Managing Partner
Phone: (646) 536-7331
Email: brett@haydenir.com
www.haydenir.com

AIkido Pharma Inc.
Phone: 212-745-1373
Email: investorrelations@aikidopharma.com
www.aikidopharma.com

View original content to download multimedia: https://www.prnewswire.com/news-releases/aikido-pharma-announces-strategic-investment-in-masterclass-301518215.html

SOURCE AIkido Pharma Inc.

Cedars-Sinai Medical Center and AIkido Pharma Inc. Enter Into Master Collaboration Agreement

NEW YORK, March 8, 2022 /PRNewswire/ — AIkido Pharma Inc. (Nasdaq: AIKI) (“AIkido” or the “Company”) today announced that the Company has entered into a Master Collaboration Agreement (MCA) with Cedars-Sinai Medical Center. The purpose of the MCA is to collaborate in the funding and commercialization of discoveries and technologies developed at Cedars-Sinai.

Cedars-Sinai is a nonprofit academic healthcare organization serving the diverse Los Angeles community and beyond. Cedars-Sinai is known for its exceptional patient care, leading-edge medical research, comprehensive healthcare education, and wide-ranging community benefit activities.

Under the MCA, AIkido will be working with Cedars-Sinai’s Technology Ventures team, whose mission is to identify, protect and support the commercialization of discoveries and technologies developed at Cedars-Sinai or its partner institutions. Cedars-Sinai Technology Ventures has had 114 patents issued for fiscal year 2021 and has 511 active technologies under development, as of July 2021.  

Anthony Hayes, CEO of AIkido Pharma stated, “Cedars-Sinai is a world class institution, and we are honored to be working with them.  The team at Technology Ventures consists of experts in intellectual property portfolio management and licensing, legal affairs and finance who have a proven track record of monetizing exceptional technology.  It’s a privilege to be involved and to be working together to advance innovative patient care and research.”

About AIkido Pharma Inc.

AIkido Pharma Inc. was initially formed in 1967 and is a biotechnology Company with a diverse portfolio of small-molecule anticancer and antiviral therapeutics. The Company’s platform consists of patented technology from leading universities and researchers, and we are currently in the process of developing an innovative therapeutic drug platform through strong partnerships with world renowned educational institutions, including The University of Texas at Austin and University of Maryland at Baltimore. Our diverse pipeline of therapeutics includes therapies for pancreatic cancer, prostate cancer. We are constantly seeking to grow our pipeline to treat unmet medical needs in oncology. The Company is also developing a broad-spectrum antiviral platform that may potentially inhibit replication of multiple viruses including Influenza virus, SARS-CoV (coronavirus), MERS-CoV, Ebolavirus and Marburg virus.

Forward-Looking Statements

Certain statements in this press release constitute “forward-looking statements” within the meaning of the federal securities laws. Words such as “may,” “might,” “will,” “should,” “believe,” “expect,” “anticipate,” “estimate,” “continue,” “predict,” “forecast,” “project,” “plan,” “intend” or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including without limitation those set forth in the Company’s filings with the SEC, not limited to Risk Factors relating to its business contained therein. Thus, actual results could be materially different. The Company expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.

Contact:

Investor Relations:     

Hayden IR
Brett Maas, Managing Partner
Phone: (646) 536-7331
Email: brett@haydenir.com
www.haydenir.com

AIkido Pharma Inc.:  

Phone: 212-745-1373
Email: investorrelations@aikidopharma.com
www.aikidopharma.com

SOURCE AIkido Pharma Inc.

AIkido Pharma Reports Improved Manufacturing Process and New United States Patent for Pancreatic Drug

NEW YORK, March 3, 2022 /PRNewswire/ — AIkido Pharma Inc. (Nasdaq: AIKI) (“AIkido” or the “Company”) today reported an improvement in the manufacturing process for its pancreatic cancer drug, DHA-dFdC, licensed from the University of Texas at Austin. The Company also reported the issuance of an additional U.S. patent covering the drug, and the filing of a continuation patent application intended to expand patent coverage to other facets of the drug.

With respect to manufacturing process, the Company reported the successful development of a new means for the scaled production and isolation of the key intermediate compound in the manufacture of DH-dFdC. The Company has now executed a further contract with its contract manufacturing organization, Parimer Scientific, to employ the new process to produce several thousand milligrams of the drug for use in formulation development and stability studies. The Company also reported that the U.S. Patent Office recently issued new U.S. Patent No. 11,219,633, which provides additional intellectual property protection for the drug compound. The term of the patent is expected to continue until May of 2035 with the payment of required maintenance fees. Prior to the patent issuance, the Company authorized the timely filing of a patent continuation application, U.S. Serial No. 17/539,682, in which additional claims related to various aspects of the drug and formulation will be pursued.

Anthony Hayes, CEO of AIkido, stated, “This new process significant step forward in the development of our pancreatic cancer drug and should permit production of the drug on a commercial scale at a lower cost. I am also pleased that we can continue to report expansion of the patent estate.”

Richard T. Pace, Owner and Principal Scientist of Parimer Scientific, stated, “The newly developed manufacturing method is a large step forward for this innovative technology. I believe it will reduce cost per unit and at the same time increase batch production volumes.”

About AIkido Pharma Inc.

AIkido Pharma Inc. was initially formed in 1967 and is a biotechnology Company with a diverse portfolio of small-molecule anticancer and antiviral therapeutics. The Company’s platform consists of patented technology from leading universities and researchers, and we are currently in the process of developing an innovative therapeutic drug platform through strong partnerships with world renowned educational institutions, including The University of Texas at Austin and University of Maryland at Baltimore. Our diverse pipeline of therapeutics includes therapies for pancreatic cancer, prostate cancer. We are constantly seeking to grow our pipeline to treat unmet medical needs in oncology. The Company is also developing a broad-spectrum antiviral platform that may potentially inhibit replication of multiple viruses including Influenza virus, SARS-CoV (coronavirus), MERS-CoV, Ebolavirus and Marburg virus.

Forward-Looking Statements

Certain statements in this press release constitute “forward-looking statements” within the meaning of the federal securities laws. Words such as “may,” “might,” “will,” “should,” “believe,” “expect,” “anticipate,” “estimate,” “continue,” “predict,” “forecast,” “project,” “plan,” “intend” or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including without limitation those set forth in the Company’s filings with the SEC, not limited to Risk Factors relating to its business contained therein. Thus, actual results could be materially different materially from those currently anticipated which include those regarding our ability to implement our plans, strategies, and objectives for future operations. The Company expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.

Contact:
Investor Relations:   
Hayden IR
Brett Maas, Managing Partner
Phone: (646) 536-7331
Email: brett@haydenir.com
www.haydenir.com

AIkido Pharma Inc.
Phone: 212-745-1373
Email: investorrelations@aikidopharma.com
www.aikidopharma.com

SOURCE AIkido Pharma Inc.